Karyopharm Announces Initiation of Phase 2 Study of Selinexor (KPT-330) in Patients with Hormone Refractory Prostate Cancer (SHIP Study)

“Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, today announced the initiation of a Phase 2 trial of its novel, oral Selective Inhibitor of Nuclear Export (SINE) compound Selinexor (KPT-330) in patients with metastatic hormone-refractory prostate cancer (HRPC). The study, referred to as the SHIP (Selinexor in Hormone Refractory Indications in Prostate Cancer) study, is led by Drs. Christopher J. Logothetis and John Araujo of the M.D. Anderson Cancer Center at the University of Texas in Houston and is being funded in part by a grant from the Prostate Cancer Foundation.”

Editor’s note: This story describes a new clinical trial to test a prostate cancer treatment in volunteer patients. The new drug is called Selinexor (aka KPT-330), and it may benefit patients who have been diagnosed with metastatic hormone-refractory prostate cancer.

Prostate Cancer Foundation and Sanofi Start Text Message Support Program for Men with Advanced Prostate Cancer

The Prostate Cancer Foundation (PCF) has joined with pharmaceutical company Sanofi to start a text message-based support program for men in the U.S. undergoing chemotherapy for advanced prostate cancer. The program, Prost8Care, is meant to provide patients with encouragement and education during a 12-week treatment course. To learn more, and to sign up, click here.

Work-Related Stress Unlikely to Cause Prostate Cancer

Researchers at the Finnish Institute of Occupational Health and University College London have conducted a meta-analysis of 12 studies to determine if job strain is related to cancer risk. Their findings suggest there is no relationship between work-related stress and overall cancer risk.

In the UK, Rate of Prostate Cancer Diagnoses Increase as Deaths from the Disease Decrease

Cancer Research UK has released figures indicating that the number of prostate cancer cases diagnosed yearly have tripled over the last 20 years. In contrast, the number of deaths from the disease have decreased by 18%. Experts suggest the increase in diagnoses is due to widespread use of PSA (prostate-specific antigen) testing and the decrease in deaths is because of earlier diagnosis and improved treatments.

Obesity Biomarkers and Prostate Cancer Study Suggests Obesity Can Accelerate Prostate Cancer Progression

A study of 500 men finds that higher body mass index, leptin blood levels, and waist-hip ratio were significantly associated with higher grade prostate cancer and suggests detection bias during prostate biopsy has resulted in
inconsistent results when the association between obesity and prostate cancer was previously studied.

A Plea for Surgical Lymph Node Staging in Advanced Prostate Cancer from European Oncologists

Clinicians advocate for a prostate cancer treatment via pelvic lymph node irradiation strategy for high-risk prostate cancer patients to be based on surgical staging. New techniques of gamma-camera-navigated surgery and fluorescence guidance to the sentinel node could improve the staging.

Targeting Constitutively Activated β1 Integrin Could Be a New Target for Prevention of Metastasis of Prostate Cancer

Researchers from the MD Anderson Cancer Center in Houston show that β1 integrin activation occurs in metastatic progression of prostate cancer and is constitutively active in late state prostate cancer cells. The study shows the integrin palys a reole in survival of metastatic prostate cancer cells in circulation. Inhibition of β1 integrin activity by antibody or knockdown results in increased apoptosis.

Prostate cancer risk reduction in men taking dutasteride, but some concerns remain

Nearly 2,800 men participated in the four-year REDUCE (REduction by DUtasteride of prostate Cancer Events) observational clinical study evaluated prostate cancer risk reduction in men taking dutasteride, a 5-alpha-reductase inhibitor (5ARI) typically used to treat enlarged prostate. Results showed that few new prostate cancers were detected during the two-year follow-up in either treatment group and no deaths were reported. However, the former dutasteride group produced double the number of cancers than the former placebo group (14 vs. 7).

Consistent epigenetic ‘signatures’ found in prostate cancer patients’ metastatic tumors

Researchers at Johns Hopkins analyzed 13 metastatic prostate tumors, finding a a consistent epigenetic signature among the samples. The discovery of the stable, epigenetic “marks” that sit on the nuclear DNA of cancer cells and alter gene expression, defies a prevailing belief that the marks vary so much within each individual’s widespread cancers that they have little or no value as targets for therapy or as biomarkers for treatment response and predicting disease severity.